Drug fever and hyperthermia

Drug fever is a febrile reaction that coincides in time with and is pathogenetically associated with the use of a drug. The review presents publications of epidemiological and clinical studies on various variants of fever development due to the use of pharmacological agents. Febrile reactions associated with both immune hypersensitivity and those with other mechanisms of development, as well as drug hypersensitivity syndromes, including fever as one of the syndromes (drug-induced hypersensitivity syndrome, serum sickness, drug-induced lupus), are considered. Most often, the term “drug fever” is used to define cases with isolated febrile increase in body temperature, not accompanied by other clinical symptoms (for example, rash or organ damage), and having an immune genesis. An association of drug fever with an extremely wide range of drugs has been established, but most often it is caused by beta-lactam antibiotics. There is a high probability of drug fever in intensive care unit patients who have a high risk of bacterial infection and receive long courses of antibiotics. Underdiagnosis of drug fever leads to unjustified continuation and intensification of antibacterial therapy, increased risk of iatrogenic complications and economic costs. The review also presents variants of drug hyperthermia: malignant neuroleptic syndrome, malignant hyperthermia, serotonin syndrome, propofol infusion syndrome and some others. Despite the long history of studying the issue, the pathogenesis of the pathology remains not entirely clear, there are no specific diagnostic markers and the diagnosis is still made by exclusion.

1. Roush MK, Nelson KM. Understanding drug-induced febrile reactions. Am Pharm. 1993;NS33(10):39–42. https://doi.org/10.1016/S0160-3450(15)30635-8.

2. Patel RA, Gallagher JC. Drug fever. Pharmacotherapy. 2010;30(1):57–69. https://doi.org/10.1592/phco.30.1.57.

3. Someko H, Kataoka Y, Obara T. Drug fever: a narrative review. Ann Clin Epidemiol. 2023;5(4):95–106. https://doi.org/10.37737/ace.23013.

4. Eidenbenz D, Hirschel T, Schürmann G, Genné D. Drug fever among Swiss’ most sold drugs in primary care. Rev Med Suisse. 2019;15(660):1516–1520. Available at: https://pubmed.ncbi.nlm.nih.gov/31496177.

5. Postnikov SS, Kostyleva MN, Gratsianskaya AN. Drug fever. Pediatriya – Zhurnal im G.N. Speranskogo. 2011;(6):125–127. (In Russ.) Available at: https://pediatriajournal.ru/archive?show=318&section=3247.

6. Vodovar D, LeBeller C, Mégarbane B, Lillo-Le-Louet A, Hanslik T. Drug Fever: a descriptive cohort study from the French national pharmacovigilance database. Drug Saf. 2012;35(9):759–767. https://doi.org/10.2165/11630640000000000-00000.

7. Mori F, Fili L, Barni S, Sarti L, Pucci N, Parronchi P. Drug fever after a single dose of amoxicillin-clavulanic acid. J Allergy Clin Immunol Pract. 2016;4(3):533–534.e1. https://doi.org/10.1016/j.jaip.2015.11.030.

8. Hama N, Abe R, Gibson A, Phillips EJ. Drug-induced hypersensitivity syndrome (DIHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): clinical features and pathogenesis. J Allergy Clin Immunol Pract. 2022;10(5):1155–1167.E5. https://doi.org/10.1016/j.jaip.2022.02.004.

9. Haidar G, Singh N. Fever of Unknown Origin. N Engl J Med. 2022;386(5):463–477. https://doi.org/10.1056/NEJMra2111003.

10. Ogar CK, Abiola A, Yuah D, Ibrahim A, Oreagba IA, Amadi EC et al. A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016. Pharmaceut Med. 2019;33(2):145–157. https://doi.org/10.1007/s40290-019-00267-2.

11. Uwai Y, Nabekura T. Analysis of adverse drug events in patients with bipolar disorders using the Japanese Adverse Drug Event Report database. Pharmazie. 2022;77:255–261. https://doi.org/10.1691/ph.2022.2386.

12. Bigi C, Tuccori M, Bocci G. Healthcare professionals and pharmacovigilance of pediatric adverse drug reactions: a 5-year analysis of Adverse Events Reporting System Database of the Food and Drug Administration. Minerva Pediatr. 2022;74(3):272–280. https://doi.org/10.23736/S2724-5276.17.04733-8.

13. Labbus K, Junkmann JK, Perka C, Trampuz A, Renz N. Antibiotic-induced fever in orthopaedic patients-a diagnostic challenge. Int Orthop. 2018;42(8):1775–1781. https://doi.org/10.1007/s00264-018-3909-8.

14. Peng W-X, Lin Y, Shi X-J. Retrospective analysis about 20 cases of drug fever induced by antibiotics. Clin Medicat J. 2017;15:16–18. https://doi.org/10.2169/internalmedicine.55.5740.

15. Yaita K, Sakai Y, Masunaga K, Watanabe H. A Retrospective Analysis of Drug Fever Diagnosed during Infectious Disease Consultation. Intern Med. 2016;55:605–608. https://doi.org/10.2169/internalmedicine.55.5740.

16. Hu Y, Han J, Gao L, Liu S, Wang H. Drug fever induced by antibiotics of β-lactams in a patient after posterior cervical spine surgery A case report and literature review. Front Surg. 2023;9:1065106. https://doi.org/10.3389/fsurg.2022.1065106.

17. Эль-Радхи Сахиб А (ред.). Лихорадка у детей. М.: ГЭОТАР-Медиа; 2022. 400 с.

18. Buck ML. Drug Fever: Recent Cases from the Medical Literature. Pediatric Pharmacotherapy. 2018;24(1). Available at: https://med.virginia.edu/pediatrics/wp-content/uploads/sites/237/2018/01/Jan18_Drug-Fever_PedPharmaco.pdf.

19. Jennings ELM, Murphy KD, Gallagher P, O’Mahony D. In-hospital adverse drug reactions in older adults; prevalence, presentation and associated drugs-a systematic review and meta-analysis. Age Ageing. 2020;49(6):948–958. https://doi.org/10.1093/ageing/afaa188.

20. Postnikov S, Teplova N, Ermilin A, Kostyleva M, Gratzyanskaya A, Eremina Yu, Chervyakova G. Fever as an Adverse Drug Reaction of Different Therapeutic Groups. Amer J Pediatr. 2020;6(4):495–503. https://doi.org/10.11648/j.ajp.20200604.28.

21. Gans MD, Tejera DS, Jerschow E. Evaluating drug fever to beta-lactam antibiotics. Ann Allergy Asthma Immunol. 2020;124(4):401–403. https://doi.org/10.1016/j.anai.2020.01.026.

22. Yuan HL, Lu NW, Xie H, Zheng YY, Wang QH. Doxycycline-induced drug fever: a case report. Infect Dis. 2016;48:844–846. https://doi.org/10.1080/23744235.2016.1195915.

23. Shen L. Fever and reversible laboratory abnormalities associated with prolonged use of piperacillin/tazobactam: A case report. SAGE Open Med Case Rep. 2024;12:2050313X241285675. https://doi.org/10.1177/2050313X241285675.

24. Yusef D, Gonzalez BE, Foster CB, Goldfarb J, Saracusa C, Worley S, Sabella C. Piperacillin-Tazobactam-induced Adverse Drug Events in Pediatric Patients on Outpatient Parenteral Antimicrobial Therapy. Pediatr Infect Dis J. 2017;36(1):50–52. https://doi.org/10.1097/INF.0000000000001351.

25. Yang J, Wang Q, Wang S, Zhang Y, Wang Z. Unusual Drug Fever Caused by Imipenem / Cilastatin and a Review of Literature. Heart Surg Forum. 2019;22(2):E119–E123. https://doi.org/10.1532/hsf.2141.

26. Lefebvre N, Forestier E, Farhi D, Mahsa MZ, Remy V, Lesens O et al. Minocyline-induced hypersensivity syndrome presenting with meningitis and brain edema: a case report. J Med Case Rep. 2007;1:22. https://doi.org/10.1186/1752-1947-1-22.

27. Scardina T, Fawcett AJ, Patel SJ. Amphotericin-Associated Infusion-Related Reactions: A Narrative Review of Pre-Medications. Clin Ther. 2021;43(10):1689–1704. https://doi.org/10.1016/j.clinthera.2021.09.011.

28. Cavassin FB, Baú-Carneiro JL, Vilas-Boas RR, Queiroz-Telles F. Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections. Infect Dis Ther. 2021;10(1):115–147. https://doi.org/10.1007/s40121-020-00382-7.

29. Grazziotin LR, Moreira LB, Ferreira MAP. Comparative effectiveness and safety between amphotericin B lipid-formulations: a systematic review. Int J Technol Assess Health Care. 2018;34(3):343–351. https://doi.org/10.1017/S026646231800034X.

30. Laniado-Laborín R, Cabrales-Vargas MN. Amphotericin B: side effects and toxicity. Rev Iberoam Micol. 2009;26(4):223–227. https://doi.org/10.1016/j.riam.2009.06.003.

31. Andrew EC, Curtis N, Coghlan B, Cranswick N, Gwee A. Adverse effects of amphotericin B in children; a retrospective comparison of conventional and liposomal formulations. Br J Clin Pharmacol. 2018;84(5):1006–1012. https://doi.org/10.1111/bcp.13521.

32. Alharbi HH, Al-Qurainees GI, Al-Hebshi A. Vancomycin-Induced Fever and Neutropenia in an Immunocompetent Patient With Complicated Community-Acquired Pneumonia. Cureus. 2022;14(7):e26630. https://doi.org/10.7759/cureus.26630.

33. Ovchinnikova EA, Ovchinnikova LK. Safety spectrum of vancomycin. Kachestvennaya Klinicheskaya Praktika. 2004;(2):36–48. (In Russ.) Available at: https://www.clinvest.ru/jour/article/view/311.

34. Zhang J, Rong C, Yan C, Chen J, Yang W, Yu L, Dai H. Risk factors of furazolidone-associated fever. PLoS ONE. 2022;17(4):e0266763. https://doi.org/10.1371/journal.pone.0266763.

35. Shin H-J, Chang J-S, Kim M-S, Koh B-G, Park H-Y, Kim T-O et al. Hypersensitivity reactions to multiple anti-tuberculosis drugs. PLoS ONE. 2021;16(2):e0246291 https://doi.org/10.1371/journal.pone.0246291.

36. Yilmaz M, Yasar C, Aydin S, Derin O, Ceylan B, Mert A. Rifampicin-Induced Fever in a Patient with Brucellosis: A Case Report. Drug Saf Case Rep. 2018;5(1):9. https://doi.org/10.1007/s40800-018-0074-3.

37. Maddock K, Connor K. Drug Fever: A Patient Case Scenario and Review of the Evidence. AACN Adv Crit Care. 2020;31(3):233–238. https://doi.org/10.4037/aacnacc2020311.

38. Ghannam M, Mansour S, Nabulsi A, Abdoh Q. Anticonvulsant hypersensitivity syndrome after phenytoin administration in an adolescent patient: a case report and review of literature. Clin Mol Allergy. 2017;15:14. https://doi.org/10.1186/s12948-017-0069-0.

39. Manship D, Swinger M, Crow A, Alexopulos J. Anticonvulsant Hypersensitivity Syndrome (AHS). Poster session presented at Oklahoma State University Center for Health Sciences Research Day 2020, Tulsa, Oklahoma, United States. Available at: https://hdl.handle.net/20.500.14446/324223.

40. Zhang X, Zhao M, Zheng C. Drug fever induced by carboplatin-based regimens: Higher incidence in a women’s hospital. Taiwan J Obstet Gynecol. 2021;60(5):882–887. https://doi.org/10.1016/j.tjog.2021.07.018.

41. Kidon MI, Haj Yahia S, Abebe-Campino G, Agmon-Levin N and Yelon M. Drug fever – an immune-mediated delayed type hypersensitivity reaction to Vinca alkaloids in pediatric oncology patients, possibly mediated by cysteinyl leukotrienes. Front Allergy. 2024;5:1361403. https://doi.org/10.3389/falgy.2024.1361403.

42. Eidenbenz D, Hirschel T, Schürmann G, Genné D. Fièvre médicamenteuse en médecine de premier recours liée aux médicaments les plus vendus en Suisse [Drug fever among Swiss’ most sold drugs in primary care]. Rev Med Suisse. 2019;15(660):1516–1520. Available at: https://pubmed.ncbi.nlm.nih.gov/31496177.

43. Melo N, Policarpo S, Dias M, Almeida J. Pantoprazole: An Unusual Suspect in a Patient with Fever. Eur J Case Rep Intern Med. 2021;8(5):002571. https://doi.org/10.12890/2021_002571.

44. Xiao J, Jia SJ, Wu CF. Celecoxib-induced drug fever: a rare case report and literature review. J Clin Pharm Ther. 2022;47(3):402–406. https://doi.org/10.1111/jcpt.13490.

45. Bhagat M, Suman S, Besra KC, Kumar T, Priye S, Bhattacharya PK, Lakra L. Morphine-Induced Fever: A Case Series. Cureus. 2022;14(4):e24402. https://doi.org/10.7759/cureus.24402.

46. Graczyk M, Krajnik M, Woroń J, Wordliczek J, Malec-Milewska M. Use of opioids as one of the causes of fever in patients with advanced cancer. Int J Immunopathol Pharmacol. 2017;30(1):98–104. https://doi.org/10.1177/0394632016686088.

47. Zhu L, Zhang Z, Ju H, Wang C, Jiang W. Morphine-induced fever: a case report and review of the literature. J Med Case Rep. 2024;18(1):449. https://doi.org/10.1186/s13256-024-04770-2.

48. Murai Y, Kawasuji H, Takegoshi Y, Kaneda M, Kimoto K, Ueno A et al. A case of COVID-19 diagnosed with favipiravir-induced drug fever based on a positive drug-induced lymphocyte stimulation test. Int J Infect Dis. 2021;106:33–35. https://doi.org/10.1016/j.ijid.2021.03.048.

49. Tawara J, Uehara T, Sakao S, Igari H, Taniguchi T, Kasai H et al. Drug Fever Due to Favipiravir Administration for the Treatment of a COVID-19 Patient. Intern Med. 2021;60(7):1115–1117. https://doi.org/10.2169/internalmedicine.5813-20.

50. Chen DH, Zhou HR, Zhang YG, Shen GY, Xu C, Guan CL. Drug hypersensitivity syndrome induced by sulfasalazine: A case report. Medicine. 2022;101(33):e30060. https://doi.org/10.1097/MD.0000000000030060.

51. Winward J, Lyckholm L, Brown SM, Mokadem M. Case of relapsing sulfasalazine-induced hypersensitivity syndrome upon re-exposure. BMJ Case Rep. 2020;13(9):e235803. https://doi.org/10.1136/dtb.2021.235803rep.

52. James J, Sammour YM, Virata AR, Nordin TA, Dumic I. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Secondary to Furosemide: Case Report and Review of Literature. Am J Case Rep. 2018;19:163–170. https://doi.org/10.12659/ajcr.907464.

53. Chashkova EYu, Pak EV, Shedoeva LR, Gerasimenko AN. Prolonged fever after induction therapy with infliximab in a patient with ulcerative colitis (clinical case). Acta Biomedica Scientifica. 2022;7(6):45–50. (In Russ.) https://doi.org/10.29413/ABS.2022-7.6.5.

54. Laun J, Laun K, Farooqi A, Smith DJ. Heparin-Induced Fever: A Case Report and Literature Review. J Burn Care Res. 2019;40(5):723–724. https://doi.org/10.1093/jbcr/irz064.

55. Gosnell H, Stein A, Vanegas Acosta DE. Postoperative fever secondary to enoxaparin usage with pork allergy. BMJ Case Rep. 2022;15(1):e246904. https://doi.org/10.1136/bcr-2021-246904.

56. Ng QX, Seng C, Ho CYX, Yeo WS. Enoxaparin: A cause of postoperative fever? Med Hypotheses. 2018;121:47–48. https://doi.org/10.1016/j.mehy.2018.09.027.

57. Ghaferi A, Shojaei M, Chouhdari A. Evaluation of Association between FluLike Syndrome Induced by Beta Interferon Drug and Required Drug Response in Patients with Multiple Sclerosis. Novelty in Biomedicine. 2019;7(4):237–245. https://doi.org/10.22037/nbm.v7i3.23085.

58. Zaplatnikov AL, Girina AA, Lepiseva IV, Svintsitskaya VI, Leshik MV, Fursova AV. Post-vaccination hyperthermia in children: a current view of the old problem. Russian Journal of Woman and Child Health. 2023;6(2):192–198. (In Russ.) https://doi.org/10.32364/2618-8430-2023-6-2-192-198.

59. Mort M, Baleta A, Destefano F, Nsubuga J, Vellozzi C, Mehta U et al. Vaccine safety basics. Learning manual. Switzerland: WHO Press, World Health Organization; 2013. Available at: https://vaccine-safety-training.org/vaccine-reactions.

60. Wei BM, Fox LP, Kaffenberger BH, Korman AM, Micheletti RG, Mostaghimi A et al. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part I. Epidemiology, pathogenesis, clinicopathological features, and prognosis. J Am Acad Dermatol. 2024;90(5):885–908. https://doi.org/10.1016/j.jaad.2023.02.072

61. Stirton H, Shear NH, Dodiuk-Gad RP. Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS)/Drug-Induced Hypersensitivity Syndrome (DiHS)-Readdressing the DReSS. Biomedicines. 2022;10(5):999. https://doi.org/10.3390/biomedicines10050999.

62. Bhatt KP, Alsoud F, Prashad A, Ortega-Tola J, Singh VR, Patel P, Michel G. Drug reaction with eosinophilia and systemic symptoms (DRESS): an unusual manifestation of multi-visceral abnormalities and long-term outcome. Discoveries. 2023;11(1):e170. https://doi.org/10.15190/d.2023.9.

63. Chen CB, Hung WK, Wang CW, Lee CC, Hung SI, Chung WH. Advances in understanding of the pathogenesis and therapeutic implications of drug reaction with eosinophilia and systemic symptoms: an updated review. Front Med. 2023;10:1187937. https://doi.org/10.3389/fmed.2023.1187937.

64. Hama N, Abe R, Gibson A, Phillips EJ. Drug-Induced Hypersensitivity Syndrome (DIHS)/Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): Clinical Features and Pathogenesis. J Allergy Clin Immunol Pract. 2022;10(5):1155–1167.e5. https://doi.org/10.1016/j.jaip.2022.02.004.

65. Someko H, Kataoka Y, Obara T. Drug fever: a narrative review. Ann Clin Epidemiol. 2023;5(4):95–106. https://doi.org/10.37737/ace.23013.

66. Shamgunova BA, Demidov AA, Zaklyakova LV, Gorbunova O., Kasymova EB, Zavyalova IN. Drug-induced hypersensitivity reaction (DRESS syndrome) associated with reactivation of herpesvirus infection (clinical observation). Modern Problems of Science and Education. 2020;(4). (In Russ.) Available at: https://science-education.ru/ru/article/view?id=30054.

67. Del Pozzo-Magaña BR, Abuzgaia A, Murray B, Rieder MJ, Lazo-Langner A. Paediatric serum sickness-like reaction: A 10-year retrospective cohort study. Paediatr Child Health. 2021;26(7):428–435. https://doi.org/10.1093/pch/pxab003.

68. Bakshi D, Tang X, Waserman S. A case of pediatric serum sickness like reaction (SSLR) after a 2-month re-exposure to amoxicillin. Allergy Asthma Clin Immunol. 2024;20(1):29. https://doi.org/10.1186/s13223-024-00887-7.

69. Podchernyaeva NS, Bayramkulov AM, Golovanova NYu, Osminina MK, Shpitonkova OV. Drug-induced lupus erythematosus. Pediatriya – Zhurnal im G.N. Speranskogo. 2023;102(5):145–155. (In Russ.) https://doi.org/10.24110/0031-403X-2023-102-5-145-155.

70. Kaya Akca U, Sener S, Batu ED, Balik Z, Basaran O, Bilginer Y, Ozen S. Druginduced lupus erythematosus in childhood: Case-based review. Lupus. 2024;33(7):737–748. https://doi.org/10.1177/09612033241245078.

71. Chang C, Gershwin ME. Drug-induced lupus erythematosus: incidence, management and prevention. Drug Saf. 2011;34(5):357–374. https://doi.org/10.2165/11588500-000000000-00000.

72. Tatochenko VK, Bakradze MD, Agaronyan AG. Jarisch-Herxheimer reaction in a child with community-acquired pneumonia: a clinical case. Pediatric Pharmacology. 2018;15(3):255–259. (In Russ.) https://doi.org/10.15690/pf.v15i3.1906.

73. Zhiburt EB, Shestakov EA, Kuznetsov SI. Hemolytic transfusion reactions. Bulletin of the National Medical and Surgical Center named after N.I. Pirogov. 2019;14(4): 105–111. (In Russ.) https://doi.org/10.25881/BPNMSC.2020.17.22.020.

74. Tidswell EC. A Nontrivial Analysis of Patient Safety Risk from Parenteral Drugand Medical Device-Borne Endotoxin. Drugs R D. 2023;(1):65–76. https://doi.org/10.1007/s40268-023-00412-y.

75. Korenev SA, Rykov SV. Forensic medical assessment of pyrogenic reactions. Problemy Ehkspertizy v Meditsine. 2003;3(4):15–17. Available at: https://cyberleninka.ru/article/n/sudebno-meditsinskaya-otsenkapirogennyh-reaktsiy.

76. Jamshidi N, Dawson A. The hot patient: acute drug-induced hyperthermia Aust Prescr. 2019;42(1):24–28. https://doi.org/10.18773/austprescr.2019.006.

77. Bongers KS, Salahudeen MS, Peterson GM. Drug-associated non-pyrogenic hyperthermia: a narrative review. Eur J Clin Pharmacol. 2020;76(1):9–16. https://doi.org/10.1007/s00228-019-02763-5.

78. Hölle T, Purrucker JC, Morath B, Weigand MA, Schmitt FCF. Central anticholinergic, neuroleptic malignant and serotonin syndromes: Important differential diagnoses in postoperative impairment of consciousness. Anaesthesiologie. 2023;72(3):157–165. https://doi.org/10.1007/s00101-023-01256-6.

79. Horseman M, Panahi L, Udeani G, Tenpas AS, Verduzco R Jr, Patel PH et al. Drug-Induced Hyperthermia Review. Cureus. 2022;14(7):e27278. https://doi.org/10.7759/cureus.27278.

80. León-Amenero D, Huarcaya-Victoria J. Neuroleptic malignant syndrome in children and adolescents: Systematic review of case reports. Rev Colomb Psiquiatr. 2021;50(4):290–300. https://doi.org/10.1016/j.rcpeng.2019.10.006.

81. Tariq M, Wentzel DN, Beggs JB. Hold off That Olanzapine! The Development of Neuroleptic Malignant Syndrome in a Dehydrated Pediatric Patient. Kans J Med. 2023;16:328–329. https://doi.org/10.17161/kjm.vol16.21303.

82. Tekin FC, Sezer C. Persistent highfever after metchloropramide treatment; neurolepticmalignant syndrome. J Emerg Med. 2022;13(4):101–103. https://doi.org/10.33706/jemcr.1068447.

83. Hopkins PM, Girard T, Dalay S, Jenkins B, Thacker A, Patteril M, McGrady E. Malignant hyperthermia 2020: Guideline from the Association of Anaesthetists. Anaesthesia. 2021;76(5):655–664. https://doi.org/10.1111/anae.15317.

84. Klincová M, Štěpánková D, Schröderová I, Klabusayová E, Štourač P. Malignant Hyperthermia in PICU-From Diagnosis to Treatment in the Light of Up-to-Date Knowledge. Children. 2022;9(11):1692. https://doi.org/10.3390/children9111692.

85. Accamma K, Shamarao S, Ram A, Devananda NS, Krishna M, Bandagi LS et al. Severe Diabetic Ketoacidosis with Malignant Hyperthermia Like Syndrome and Rhabdomyolysis Treated with ECMO: Unusual Severity and a Rare Occurrence. Indian J Crit Care Med. 2023;27(11):859–860. https://doi.org/10.5005/jp-journals-10071-24569.

86. Xuev S, Ickowicz A. Serotonin Syndrome in Children and Adolescents Exposed to Selective Serotonin Reuptake Inhibitors – A Review of Literature. J Can Acad Child Adolesc Psychiatry. 2021;30(3):156–164. Available at: https://pubmed.ncbi.nlm.nih.gov/34381508.

87. Chiew AL, Buckley NA. The serotonin toxidrome: shortfalls of current diagnostic criteria for related syndromes. Clin Toxicol. 2022;60(2):143–158. https://doi.org/10.1080/15563650.2021.1993242.

88. Markov YuI. Anticholinergic syndrome (lecture). Emergency Medicine. 2017;(1):17–20. (In Ukrain.) Available at: https://cyberleninka.ru/article/n/antiholinergicheskiy-sindrom-lektsiya.

89. Krajčová A, Waldauf P, Anděl M, Duška F. Propofol infusion syndrome: a structured review of experimental studies and 153 published case reports. Crit Care. 2015;19:398. https://doi.org/10.1186/s13054-015-1112-5.

90. Peterson J, Thomas W, Michaud C, Parker J. Incidence of Fever Associated With Dexmedetomidine in the Adult Intensive Care Unit. J Pharm Pract. 2022;35(5):716–721. https://doi.org/10.1177/08971900211004828.

91. Schurr JW, Ambrosi L, Lastra JL, McLaughlin KC, Hacobian G, Szumita PM. Fever Associated With Dexmedetomidine in Adult Acute Care Patients: A Systematic Review of the Literature. J Clin Pharmacol. 2021;61(7):848–856. https://doi.org/10.1002/jcph.1826.